Literature DB >> 22900617

Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.

Zaibo Li1, R Marshall Austin, Ming Guo, Chengquan Zhao.   

Abstract

CONTEXT: The limitations of newer cervical screening tests are still being studied.
OBJECTIVE: To investigate those limitations, we conducted a retrospective review of 287 cases of cervical squamous cell carcinoma (SCC).
DESIGN: A search through 5 years of records identified 287 women with cervical SCC diagnoses. Clinical history, histopathology, and liquid-based cytology (ThinPrep) and Hybrid Capture 2 (HC2) high-risk human papillomavirus (HPV) results were documented. Polymerase chain reaction HPV tests were performed on SCC tissues with prior negative HC2 results.
RESULTS: Of 287 women, 156 (54.4%) had abnormal cytology results, and 75 (26.1%) had abnormal clinical findings triggering tissue diagnoses of SCC. Among 156 patients with abnormal Papanicolaou (Pap) test results, more-seriously abnormal Pap test results were reported in 142 women (91.1%). Among 31 women with Pap and HC2 HPV cotesting within 1 year of SCC diagnoses, 28 (90%) were Pap⁺/HPV⁺, 2 (15.5%) were Pap⁺/HPV⁻, and 1 (3%) was Pap⁻/HPV⁻. Two of 3 women with negative HC2 results before SCC diagnosis had abnormal Pap results; 1 had negative Pap reports with questionable lesional cells mimicking atrophy. In all 3 cases of SCC with negative HC2 results, HPV-18 was detected; in 2 cases (66%), HPV-16 was also detected.
CONCLUSIONS: Although abnormal cytology preceded most SCC diagnoses, about one-third of patients were referred for diagnostic testing because of clinical suspicion alone. Among 31 SCC cases with liquid-based cytology and high-risk HPV cotest results less than 1 year before SCC diagnoses, 2 patients (6.5%) had Pap⁺/HPV⁻ results, and 1 patient (3.2%) had Pap⁻/HPV⁻ results. Polymerase chain reaction detected high-risk HPV DNA in tumor tissues of 3 SCC cases with recent HC2⁻ results.

Entities:  

Mesh:

Year:  2012        PMID: 22900617     DOI: 10.5858/arpa.2011-0609-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

Review 1.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.

Authors:  Amy J Blatt; Ronald Kennedy; Ronald D Luff; R Marshall Austin; Douglas S Rabin
Journal:  Cancer Cytopathol       Date:  2015-04-10       Impact factor: 5.284

3.  Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China.

Authors:  Liran Zhang; Fengxiang Xie; Xinguo Wang; Dezhi Peng; Chunrui Bi; Lingbo Jiang; Dongman Zhao; Xinxin Tian; Debo Qi
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

4.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Sonya Naryshkin; R Marshall Austin
Journal:  Drug Healthc Patient Saf       Date:  2012-11-02

5.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Keith V Nance
Journal:  Drug Healthc Patient Saf       Date:  2013-01-21

6.  Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.

Authors:  Fengxiang Xie; Liran Zhang; Dongman Zhao; Xuefen Wu; Mingsong Wei; Xuelian Zhang; Xiaohui Wu; Hao Fang; Xue Xu; Meng Yang; Debo Qi
Journal:  BMC Infect Dis       Date:  2019-11-11       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.